IRIS
LO COCO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 124.500
EU - Europa 7.024
AS - Asia 2.026
Continente sconosciuto - Info sul continente non disponibili 46
SA - Sud America 42
OC - Oceania 17
AF - Africa 11
Totale 133.666
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 124.461
UA - Ucraina 1.555
CN - Cina 1.164
DE - Germania 1.158
IE - Irlanda 1.082
PL - Polonia 785
KR - Corea 691
IT - Italia 627
FR - Francia 544
GB - Regno Unito 383
FI - Finlandia 368
SE - Svezia 291
RU - Federazione Russa 90
EU - Europa 35
BE - Belgio 33
CA - Canada 32
JP - Giappone 30
IN - India 27
NL - Olanda 27
CL - Cile 18
BR - Brasile 17
AU - Australia 15
VN - Vietnam 15
AT - Austria 13
HK - Hong Kong 13
SK - Slovacchia (Repubblica Slovacca) 13
IR - Iran 12
SG - Singapore 11
A2 - ???statistics.table.value.countryCode.A2??? 9
ES - Italia 8
RO - Romania 8
KG - Kirghizistan 7
MX - Messico 7
UZ - Uzbekistan 7
CH - Svizzera 6
PH - Filippine 6
TR - Turchia 6
GR - Grecia 5
MA - Marocco 5
NO - Norvegia 5
AE - Emirati Arabi Uniti 4
EG - Egitto 4
HU - Ungheria 4
MY - Malesia 4
PT - Portogallo 4
RS - Serbia 4
DK - Danimarca 3
ID - Indonesia 3
LK - Sri Lanka 3
PE - Perù 3
SA - Arabia Saudita 3
TW - Taiwan 3
A1 - Anonimo 2
AM - Armenia 2
AR - Argentina 2
BD - Bangladesh 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
IL - Israele 2
IQ - Iraq 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NZ - Nuova Zelanda 2
QA - Qatar 2
AL - Albania 1
BY - Bielorussia 1
EE - Estonia 1
JO - Giordania 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
PK - Pakistan 1
SC - Seychelles 1
SI - Slovenia 1
Totale 133.666
Salva come PNG Salva come JPEG
Città #
Woodbridge 40.476
Wilmington 33.239
Houston 30.671
Fairfield 3.701
Ann Arbor 3.125
Chandler 2.041
Ashburn 1.599
Seattle 1.548
Cambridge 1.310
Jacksonville 1.164
Dublin 1.051
Dearborn 1.007
Medford 821
Kraków 771
Beijing 529
Lawrence 386
New York 311
Rome 203
San Diego 177
Zhengzhou 105
Hangzhou 102
Milan 102
Mülheim 95
Norwalk 86
Menlo Park 81
Hefei 69
London 64
Redwood City 63
Mountain View 62
Verona 60
Boardman 42
Nanjing 42
Shanghai 37
Kunming 36
Brussels 31
Creede 31
Guangzhou 31
Falls Church 25
Fuzhou 25
Chicago 23
San Francisco 23
San Mateo 22
Jinan 20
Nanchang 20
Toronto 20
University Park 20
Indiana 19
Helsinki 18
Los Angeles 18
Hounslow 17
Saint Petersburg 17
Center 15
Chengdu 15
Groningen 14
Phoenix 14
Bologna 13
Kilburn 13
São Paulo 12
Chiswick 11
Palo Alto 11
Dong Ket 10
Washington 10
Wuhan 10
Detroit 9
Redmond 9
Auburn Hills 7
Hebei 7
Innsbruck 7
Prescot 7
Santa Clara 7
Seoul 7
Tokyo 7
Changsha 6
Hong Kong 6
Kosice 6
Nürnberg 6
Quzhou 6
Shenyang 6
Shenzhen 6
Warsaw 6
Ypsilanti 6
Cedarhurst 5
Council Bluffs 5
Engelhard 5
Hanoi 5
Hanover 5
La Canada Flintridge 5
Leawood 5
Lodi 5
Montreal 5
Mumbai 5
Turin 5
Wenzhou 5
Amsterdam 4
Baotou 4
Belgrade 4
Berlin 4
Cairo 4
Chaoyang 4
Clearwater 4
Totale 125.913
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 539
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer 447
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation 443
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 439
A case of SRSF2 mutation in chronic lymphocytic leukemia 439
What is the standard regimen for patients with acute promyelocytic leukemia? 438
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 437
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells 437
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 434
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide 430
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 429
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies 426
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia 426
"Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin 426
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States 424
MiR-21 is overexpressed in NPM1-mutant acute myeloid leukemias 424
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 422
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 422
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 422
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 421
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 420
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 419
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 418
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen 418
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 417
A systems medicine clinical platform for understanding and managing non- communicable diseases 417
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 416
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 415
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 414
Current management of newly diagnosed acute promyelocytic leukemia 414
Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: Impact on response to chemotherapy 414
A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes 414
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts 413
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors 413
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL 411
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 410
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 409
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 409
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 409
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 409
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet 407
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid 407
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome [10] 406
Acute myeloid leukemia developing in patients with autoimmune diseases. 406
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 403
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. 403
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 403
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia 402
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia 401
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression 401
Molecular characterization of Ph' + hybrid acute leukemia 401
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 400
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy 400
Idiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphoma 400
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes 399
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children 399
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 399
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia 398
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy 397
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 397
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene 397
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia 396
History of acute promyelocytic leukemia: a tale of endless revolution 396
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease 395
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels 394
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 394
Panobinostat for the treatment of acute myelogenous leukemia 394
Thrombo-hemorrhagic deaths in acute promyelocytic leukemia 393
Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia 393
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? 393
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo 393
Absence of HHV-8 DNA sequences in malignant mesothelioma 393
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 393
Podocalyxin is expressed in normal and leukemic monocytes 392
Frequency of RAS and p53 mutations in acute promyelocytic leukemias 392
Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms 392
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. 392
Clonal evolution in therapy-related neoplasms 391
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. 390
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia 390
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission 390
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 389
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias 389
High-mobility group A1 proteins are overexpressed in human leukaemias 389
RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia 388
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients 388
BCL-6 and the molecular pathogenesis of B-cell lymphoma 388
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men 387
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem 387
BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma 385
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma 385
Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis 384
Arsenic trioxide: its use in the treatment of acute promyelocytic leukemia 383
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis 383
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective 383
Molecular monitoring of hematologic malignancies: current and future issues 383
Current treatment of acute promyelocytic leukemia. 382
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease 382
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features 382
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia 381
Totale 40.604
Salva come PNG Salva come JPEG
Categoria #
all - tutte 224.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 224.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197.669 0 0 0 0 0 0 0 0 0 0 3.726 3.943
2019/202036.925 3.224 2.716 2.906 3.589 3.100 4.078 3.442 3.283 3.213 2.868 1.960 2.546
2020/202119.108 2.077 2.389 2.084 2.576 1.999 2.025 2.262 1.825 500 360 829 182
2021/20223.670 152 522 124 163 94 232 222 185 210 286 404 1.076
2022/20235.075 583 257 189 623 454 1.226 447 357 547 39 246 107
2023/20241.209 230 76 118 35 185 371 33 112 17 32 0 0
Totale 134.794